RxDoctor Payments Data

Vincent Scott, MD

Urogynecology and Reconstructive Pelvic Surgery · Mobile, ALNPI 1699740027

Payments from drug & device makers

What this record shows

The money is spread across several categories — travel and lodging (50.0%), food and beverage and education — rather than concentrated in one kind of arrangement. 16 manufacturers reported payments, led by Coloplast at 40.5% of the total. Reporting peaked in 2019 at $3,308 and has fallen 69.2% since, to $1,019 in 2025.

$10,497in general payments, 2019–2025

Across 115 payments — averaging $91.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Coloplast$4K
  • Medtronic$3K
  • Boston Scientific$2K
  • Bluewind Medical$370
  • Axonics, Inc.$303
  • Caldera Medical, Inc$193
  • plus $308 from 10 others

What the payments were for

  • Travel & lodging$5,24950%
  • Food & beverage$5,18849%
  • Education$611%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few urogynecology and reconstructive pelvic surgery providers in Alabamato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$4,915
Medicare patients
18
Services billed
33

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron23$23,353
MyrbetriqMirabegron22$14,995
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst14$289

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$49$23,35323 claims
Astellas Pharma US IncMyrbetriq$55$14,99522 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few urogynecology and reconstructive pelvic surgery providers in Alabamaon file to place this against a meaningful peer group, so we don't.

Other urogynecology and reconstructive pelvic surgery in Mobile

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →